<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624143</url>
  </required_header>
  <id_info>
    <org_study_id>antifungal prophylaxis</org_study_id>
    <secondary_id>Dr. SAMEER BAKHSHI</secondary_id>
    <nct_id>NCT00624143</nct_id>
  </id_info>
  <brief_title>Antifungal Prophylaxis in Pediatric Acute Leukemia</brief_title>
  <official_title>Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:Oral Voriconazole will be as effective as intravenous Amphotericin B as antifungal&#xD;
      prophylaxis in induction of acute leukemia (ALL, AML) in pediatric patients, with less&#xD;
      toxicity and more convenience.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE OF STUDY:&#xD;
&#xD;
        -  In induction chemotherapy for childhood acute leukemia, our experience and international&#xD;
           studies has shown that 30% of ALL and approximately 50% of AML patients require&#xD;
           antifungal therapy. Mortality rates associated with documented fungal infection due to&#xD;
           opportunistic yeasts and filamentous fungi have been high, ranging from 50-90% despite&#xD;
           use of therapeutic amphotericin B or voriconazole.&#xD;
&#xD;
        -  Currently licensed drug for use in pediatric patients are amphotericin B and its lipid&#xD;
           derivatives; 5-flucytosine; azoles like fluconazole, itraconazole, voriconazole; and&#xD;
           caspofungin.&#xD;
&#xD;
        -  Limitation with Fluconazole- inactive against Aspergilosis, C. glabrata, C. krusei, C.&#xD;
           parapsilosis and filamentous fungi.&#xD;
&#xD;
        -  Limitation with Itraconazole- erratic oral absorption of capsule form, frequent drug&#xD;
           interactions, non availability of oral suspension form for use in very small children&#xD;
           who would not be able to take capsules.&#xD;
&#xD;
        -  Amphotericin B and Voriconazole both have proven activity against filamentous fungi and&#xD;
           candida species.&#xD;
&#xD;
        -  There is no prospective, randomised trial comparing voriconazole and amphotericin B in&#xD;
           prophylaxis of pediatric acute leukemia during induction.&#xD;
&#xD;
      Hence there is need to study their role in prophylaxis of this infection which has a high&#xD;
      mortality despite therapy.&#xD;
&#xD;
      Study design: Prospective, Randomized, concealed, single institutional study.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Pediatric patients of acute leukaemia who undergo induction chemotherapy at IRCH between Jan&#xD;
      2008 to Dec 2009 will be eligible for the study.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients age less than or equal to 15 years with de novo acute leukemia undergoing&#xD;
           induction chemotherapy.&#xD;
&#xD;
        -  No evidence of fungal infection at randomization&#xD;
&#xD;
        -  No pneumonia at presentation.&#xD;
&#xD;
        -  No systemic antifungal therapy within 7 days before randomization.&#xD;
&#xD;
      Febrile patients with no pneumonia, systemic fungal infection and hemodynamically stable will&#xD;
      be eligible for study.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Patients with baseline pneumonia.&#xD;
&#xD;
        -  Laboratory evidence of significant hepatic or renal dysfunction (defined as a SGOT or&#xD;
           SGPT more than 5 times, Total bilirubin more than 2 times and Serum creatinine more than&#xD;
           2 times upper limit of normal)&#xD;
&#xD;
      End points:&#xD;
&#xD;
        -  Proven or probable invasive fungal infection.&#xD;
&#xD;
        -  Initiation of full dose parental antifungal therapy for proven or probable invasive&#xD;
           fungal infection.&#xD;
&#xD;
        -  Successful recovery of ANC more than 1000/cumm or completion of induction.&#xD;
&#xD;
      Study protocol:&#xD;
&#xD;
        -  After signing informed consent forms patients will be randomly assigned to a regimen of&#xD;
           oral Voriconazole or IV low dose Amphotericin B.&#xD;
&#xD;
        -  Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12&#xD;
           hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice.&#xD;
&#xD;
        -  Patient will be started at the time of initiation of induction till completion of&#xD;
           induction.&#xD;
&#xD;
      Evaluation:&#xD;
&#xD;
      - Patients will be evaluated at baseline, twice weekly for duration of study and at&#xD;
      completion of study.&#xD;
&#xD;
      Baseline evaluation:&#xD;
&#xD;
        -  History and physical examination.&#xD;
&#xD;
        -  Hemogram and biochemistry&#xD;
&#xD;
        -  Chest X ray&#xD;
&#xD;
      Evaluation of patients with baseline fever:&#xD;
&#xD;
      For the patient presenting with fever at baseline (randomization), blood and urine culture&#xD;
      for fungus and bacteria will be send, X- ray chest to rule out consolidation at baseline will&#xD;
      be done in all patients. The patients will be started on antibiotics as per the routine&#xD;
      institutional policy. If patient becomes afebrile before day 5, then antibiotics will be&#xD;
      continued for 5 days after becoming afebrile. If patient is still febrile at day 5, then&#xD;
      empiric therapeutic antifungal therapy will be added.&#xD;
&#xD;
      Evaluation of patients with breakthrough fever:&#xD;
&#xD;
      In case of patient developing fever &gt;38 degree C (axillary) during induction chemotherapy,&#xD;
      patient will be evaluated by clinical examination, hemogram ,biochemistry, chest X ray, blood&#xD;
      and urine culture for fungus and bacterial for three consecutive days. Patients with evidence&#xD;
      of chest infection on chest X ray/signs and symptoms of chest infection/febrile even after&#xD;
      receiving 5 days of appropriate antibiotics will be subjected to HRCT scan of chest. Patients&#xD;
      showing consolidation , or signs of chest infection on chest CT will be subjected for&#xD;
      broncoscopy and bronchoalveolar lavage. The brochoalveolar lavage will be sent for microscopy&#xD;
      (gram staining), culture for fungal and bacterial growth. Full dose therapeutic antifungal&#xD;
      will be started earlier in case of development of pneumonia, hemodynamic instability even if&#xD;
      before 5 days of antibiotics which will be considered as failure of prophylaxis. Whenever&#xD;
      feasible (not mandatory) depending on the patient's clinical condition, we will try to obtain&#xD;
      tissue sample for histology by FNAC/Biopsy from the suspected infected site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of possible, probable or proven fungal infection.</measure>
    <time_frame>Completion of Induction Chemotherapy or successful recovery of ANC &gt; 1000/mm3</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pediatric Acute Leukemia Induction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Voriconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Amphotericin B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORAL VORICONAZOLE and IV Amphotericin B</intervention_name>
    <description>Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC &gt;1000/MM3 or development of fungal infection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age &lt;/= 15 years with de novo acute leukemia (AML, ALL) undergoing induction&#xD;
             chemotherapy.&#xD;
&#xD;
          -  No evidence of fungal infection at randomization&#xD;
&#xD;
          -  No pneumonia at presentation on CXR.&#xD;
&#xD;
          -  No systemic antifungal therapy within 7 days before randomization.&#xD;
&#xD;
        Febrile patients with no pneumonia, systemic fungal infection and hemodynamically stable&#xD;
        will be eligible for study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with baseline pneumonia on CXR.&#xD;
&#xD;
          -  Laboratory evidence of significant hepatic or renal dysfunction (defined as a SGOT or&#xD;
             SGPT &gt;5 times, Total bilirubin&gt;2 times and Serum creatinine &gt; 2 times upper limit of&#xD;
             normal)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SAMEER BAKHSHI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Rotary Cancer Hospital, All India Institute of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SAMEER BAKHSHI, MD</last_name>
    <phone>91-11-26588153</phone>
    <email>sambakh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute Rotary Cancer Hospital, All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAMEER BAKHSHI, MD</last_name>
      <phone>91-11-26588153</phone>
      <email>sambakh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <last_update_submitted>February 19, 2008</last_update_submitted>
  <last_update_submitted_qc>February 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Sameer Bakhshi, Associate Professor, Medical Oncology, IRCH, AIIMS, New Delhi</name_title>
    <organization>Dr.Sameer Bakhshi</organization>
  </responsible_party>
  <keyword>Antifungal prophylaxis, acute leukemia induction,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

